GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT00404274
- Locations
- πΊπΈ
GSK Investigational Site, Buffalo, New York, United States
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT00404378
- Locations
- πΊπΈ
GSK Investigational Site, Lenexa, Kansas, United States
A Combination Therapy In Patients With Social Anxiety Disorder
- Conditions
- Social Phobia
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 204
- Registration Number
- NCT00403962
- Locations
- πΏπ¦
GSK Investigational Site, Tygerberg, South Africa
Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814
- Conditions
- Hepatitis B, ChronicChronic Hepatitis B
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2010-12-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT00403585
- Locations
- π°π·
GSK Investigational Site, Seoul, Korea, Republic of
Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
- Conditions
- Fibrillation, Atrial
- Interventions
- Drug: PlaceboDrug: omega-3-acid ethyl esters
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 663
- Registration Number
- NCT00402363
- Locations
- πΊπΈ
GSK Investigational Site, Wausau, Wisconsin, United States
A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: GW786034 (pazopanib)Drug: Probe drugs
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00401583
- Locations
- πΈπ¬
GSK Investigational Site, Singapore, Singapore
A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers
- Conditions
- Irritable Bowel Syndrome (IBS)
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00401479
- Locations
- πΊπΈ
GSK Investigational Site, Rochester, Minnesota, United States
A First Time In Human Study To Assess The Compound GSK615915
- Conditions
- Bronchospasm
- Interventions
- Drug: GSK615915ADrug: Placebo
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT00400660
- Locations
- π¬π§
GSK Investigational Site, Edinburgh, West Lothian, United Kingdom
A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS
- Conditions
- Asthma
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00400608
- Locations
- πΊπΈ
GSK Investigational Site, Medford, Oregon, United States
Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 49
- Registration Number
- NCT00400855
- Locations
- π³πΏ
GSK Investigational Site, Wellington, New Zealand